Invetx is a pioneering animal health biopharmaceutical company building the world’s premier biotechnology platform for protein-based therapeutics in animal health.
Invetx features the most comprehensive solution portfolio for fit and customization.
Invetx was founded in 2018 by Juergen Horn and is headquartered in Boston, Massachusetts.
Invetx was created to translate the biotechnology revolution that has transformed human medicine to the world of animal health.
Invetx partners with best-in-class biotechnology companies to apply their deep expertise and extensive capabilities for the discovery and development of novel and advanced veterinary biotherapeutics.
Invetx has also established an animal health collaboration with Vancouver-based AbCellera, which will use its proprietary platform for antibody discovery to accelerate Invetx’s preclinical activities.
Invetx has raised $15M in a Series A round on Feb 24, 2020. The investment was led by Anterra Capital, alongside with WuXi Biologics and AbCellera.